From: Efficacy and safety of lenvatinib monotreatment and lenvatinib-based combination therapy for patients with unresectable hepatocellular carcinoma: a retrospective, real-world study in China
LEN (n = 39)
First-line treatment (n = 27)
Second-line treatment (n = 12)
CR
0
PR
5
1
SD
12
9
PD
10
2
ORR
19%
8%
DCR
63%
83%